Journal article icon

Journal article

Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.

Abstract:

OBJECTIVES: Pharmacokinetic studies were performed on the first 28 patients enrolled in a phase I trial to determine the ability of EF5 [2-(2-nitro-1-H-imidazolI-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] to detect hypoxia in human tumors in the absence of patient toxicity. METHODS: EF5 was made in purified form and formulated for intravenous injection by the National Cancer Institute. After obtaining consent from the patients, EF5 was administered and blood samples were drawn at various ...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1007/s002800100324

Authors


Rockwell, K More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Oncology
Expand authors...
Journal:
Cancer chemotherapy and pharmacology
Volume:
48
Issue:
3
Pages:
177-187
Publication date:
2001-09-05
DOI:
EISSN:
1432-0843
ISSN:
0344-5704
URN:
uuid:89288378-b005-4aa2-86df-c472eced8279
Source identifiers:
118183
Local pid:
pubs:118183

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP